Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

2
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
2
Drug Therapy01:28

Drug Therapy

423
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
423
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson's Disease.

Cannabis and cannabinoid research·2026
Same author

Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease.

Headache·2026
Same author

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

Neurodegenerative disease management·2026
Same author

Closing the Gate Before the Horse is out of the Barn: A Model to Effectively Predict the First Fall in Patients with Parkinson's Disease.

Movement disorders clinical practice·2026
Same author

Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.

Parkinsonism & related disorders·2026
Same author

Lifting the veil: Interpreting phenotypic fluidity in functional movement disorders.

Parkinsonism & related disorders·2026

Related Experiment Video

Updated: Apr 18, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.4K

[Emerging new therapies for relapsing remitting multiple sclerosis].

Saar Anis1, Anat Achiron

  • 1Neurology Department, Sourasky Medical Center, Tel Aviv, Israel.

Harefuah
|January 8, 2015
PubMed
Summary

New oral disease-modifying drugs offer improved efficacy and safety for relapsing remitting multiple sclerosis, complementing traditional injectable treatments. This review covers emerging therapies, their administration, mechanisms, and side effects.

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

28.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K

Related Experiment Videos

Last Updated: Apr 18, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.4K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

28.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K

Area of Science:

  • Neurology
  • Immunology

Context:

  • The standard treatment for relapsing remitting multiple sclerosis (RRMS) for two decades involved injectable disease-modifying drugs like interferon-beta and glatiramer acetate.
  • Recent advancements have introduced novel disease-modifying drugs with comparable or superior efficacy and safety profiles.

Purpose:

  • To review innovative and emerging disease-modifying drugs for RRMS.
  • To discuss administration methods, mechanisms of action, efficacy, safety, and side effects of these new therapies.

Summary:

  • The review contrasts traditional injectable therapies with newer oral and other emerging disease-modifying drugs for RRMS.
  • It details the administration, mechanism of action, efficacy, and safety profiles of these advanced treatments.
  • Key side effects and clinical considerations for emerging RRMS therapies are also addressed.

Impact:

  • Provides clinicians with an updated overview of RRMS treatment options.
  • Facilitates informed decision-making regarding the selection of disease-modifying drugs for RRMS patients.
  • Highlights the evolving landscape of multiple sclerosis therapeutics.